Feb 27, 2011 - 7:07 pm
For those of us with COPD -
On sale in Europe already, the Neohaler paired with Spiriva appears to work better than Advair + Spiriva!
U.S. FDA advisory meetings through March 31:
PULMONARY-ALLERGY DRUGS ADVISORY COMMITTEE
The committee will discuss Novartis AG's (NOVN.VX) (NVS.N) new drug application for its Arcapta Neohaler, also known by its chemical name indacaterol maleate, for the long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
I hope we'll be seeing this soon!